Anti-colorectal cancer of Ardisia gigantifolia Stapf. and targets prediction via network pharmacology and molecular docking study

BMC Complementary Medicine and Therapies

Research

Xianjing Hu¹  Weibo Dai²  Weijie Peng²  Xin Liu²  Jing Yang³  Quanxi Mei⁴ 

[1]Guangdong Provincial Key Laboratory of Research and Development of Natural Drugs, School of Pharmacy, Guangdong Medical University, 523808, Dongguan, PR China

[2]Pharmacology Laboratory, Zhongshan Hospital, Guangzhou University of Chinese Medicine, 528401, Zhongshan, PR China

[3]Pharmacology Laboratory, Zhongshan Hospital, Guangzhou University of Chinese Medicine, 528401, Zhongshan, PR China

[4]Zhongshan Torch Development Zone People’s Hospital, 528401, Zhongshan, PR China

[5]Shenzhen Baoan Authentic TCM Therapy Hospital, 518101, Shenzhen, PR China

关键词: Ardisia gigantifolia;    Chinese herbal medicine;    Colorectal cancer;    Network pharmacology;    Mechanism prediction;    Molecular docking;    Molecular dynamics simulation;   

DOI  :  10.1186/s12906-022-03822-8

 received in 2022-03-27, accepted in 2022-12-09,  发布年份 2022

来源: Springer

【 摘 要 】

BackgroundArdisia gigantifolia Stapf. (AGS), a Chinese folk medicine widely grows in the south of China and several studies reported that AGS could inhibit the proliferation of breast cancer, liver cancer, and bladder cancer cell lines. However, little is known about its anti-colorectal cancer (CRC) efficiency.MethodsIn the present study, a combination of MTT assay, network pharmacological analysis, bioinformatics, molecular docking, and molecular dynamics simulation study was used to investigate the active ingredients, and targets of AGS against CRC, as well as the potential mechanism.ResultsMTT assay showed that three kinds of fractions from AGS, including the n-butanol extract (NBAGS), ethyl acetate fraction (EAAGS), and petroleum ether fraction (PEAGS) significantly inhibited the proliferation of CRC cells, with the IC50 values of 197.24, 264.85, 15.45 µg/mL on HCT116 cells, and 523.6, 323.59, 150.31 µg/mL on SW620 cells, respectively. Eleven active ingredients, including, 11-O-galloylbergenin, 11-O-protocatechuoylbergenin, 11-O-syringylbergenin, ardisiacrispin B, bergenin, epicatechin-3-gallate, gallic acid, quercetin, stigmasterol, stigmasterol-3-o-β-D-glucopyranoside were identified. A total of 173 targets related to the bioactive components and 21,572 targets related to CRC were picked out through database searching. Based on the crossover targets of AGS and CRC, a protein-protein interaction network was built up by the String database, from which it was concluded that the core targets would be SRC, MAPK1, ESR1, HSP90AA1, MAPK8. Besides, GO analysis showed that the numbers of biological process, cellular component, and molecular function of AGS against CRC were 1079, 44, and 132, respectively, and KEGG pathway enrichment indicated that 96 signaling pathways in all would probably be involved in AGS against CRC, among which MAPK signaling pathway, lipid, and atherosclerosis, proteoglycans in cancer, prostate cancer, adherens junction would probably be the major pathways. The docking study verified that AGS had multiple ingredients and multiple targets against CRC. Molecular dynamics (MD) simulation analysis showed that the binding would be stable via forming hydrogen bonds.ConclusionOur study showed that AGS had good anti-CRC potency with the characteristics of multi-ingredients, -targets, and -signaling pathways.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

41116_2022_35_Article_IEq133.gif

41116_2022_35_Article_IEq131.gif

41116_2022_35_Article_IEq125.gif

41116_2022_35_Article_IEq124.gif

41116_2022_35_Article_IEq123.gif

41116_2022_35_Article_IEq122.gif

Fig. 2

42004_2022_796_Article_IEq4.gif

41116_2022_35_Article_IEq119.gif

41116_2022_35_Article_IEq118.gif

41116_2022_35_Article_IEq117.gif

41116_2022_35_Article_IEq116.gif

41116_2022_35_Article_IEq112.gif

41116_2022_35_Article_IEq105.gif

41116_2022_35_Article_IEq87.gif

Fig. 5

41116_2022_35_Article_IEq65.gif

41116_2022_35_Article_IEq58.gif

Fig. 1

Fig. 4